Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Share price of Bristol Myers Squibb (BMY) touched a 52-week low of $42.96 on July 31, post its second-quarter earnings release. The stock has recovered 6.7% since then and is currently trading at ...

Bristol-Myers Squibb Company (NYSE:BMY) ranks among the 14 safe stocks to buy now for a starter stock portfolio. On February 23, Piper Sandler boosted its price target for Bristol-Myers Squibb Company ...

Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast a dominant position in the lucrative oncology space. Oncology or ...

At first glance, Bristol-Myers Squibb appears cheap with a low P/E and strong dividend yield. GAAP earnings are consistently much lower than non-GAAP figures, reflecting costs which may limit cash ...

Combining Trinity's high yield and Bristol Myers' defensive dividend growth can enhance both income and total return for ...

Investors in Bristol Myers Squibb Co. (Symbol: BMY) saw new options begin trading today, for the December 26th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

Bristol Myers Squibb’sBMY boasts a deep and promising pipeline. Key pipeline candidates with multi-billion-dollar potential are milvexian (Oral factor XIa inhibitor), admilparant (LPA1 antagonist) ...

Bristol Myers Squibb & Co. (NYSE:BMY) on Tuesday announced results from the Phase 3 EXCALIBER-RRMM study evaluating iberdomide, an investigational cereblon E3 ligase modulator (CELMoD), combined with ...